Share on LinkedInShare on LinkedIn

ARTICLE · 26 JANUARY 2015

ECJ: Non-Fertilised Human Ovum Activated By Parthenogenesis Could Be Patentable

De Brauw Blackstone Westbroek
De Brauw Blackstone Westbroek
Contributor
De Brauw Blackstone Westbroek

De Brauw Blackstone Westbroek

Our clients are increasingly operating in South-East Asia and require legal assistance in the...

View firm profile
Explore more from De Brauw Blackstone Westbroek

The European Court of Justice recently ruled in International Stem Cell Corporation that parthenogenetically activated non-fertilised human ova are not human embryos.

NetherlandsIntellectual Property

The European Court of Justice recently ruled in International Stem Cell Corporation that parthenogenetically activated non-fertilised human ova are not human embryos in the sense of Article 6(2) of the Biotech Directive if they do not have the inherent capacity of developing into human beings. This means that the use of such cells is not excluded from patentability under Article 6(2). This judgment refines the ECJ's ruling in Brüstle and is important for stem cell technologies. However, it remains unclear whether subject matter as included in International Stem Cell Corporation's patent application can withstand the more general test of Article 6(1) of the same directive.

In International Stem Cell Corporation (ISCO), the European Court of Justice further delineated the words 'human embryos' in Article 6(2)(c) of the Biotech Directive. This article excludes the use of human embryos for industrial or commercial purposes from patentability.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from